跳至主要内容
临床试验/NCT02114619
NCT02114619Unknown不适用

The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease

Mashhad University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2013年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
450
试验地点
1
主要终点
change of thyroid related hormones blood level from baseline at 1,3,6 and 12 month

研究概览

简要总结

Radioactive iodine (RAI) administration is an effective and completely established treatment modality in hyperthyroidism including Graves' disease. Despite the long experience with radioiodine for hyperthyroidism, controversy remains regarding the optimal dose of iodine that is required to achieve long-term euthyroidism. The fixed activity administration method does not optimize the therapy, giving often too high or too low radiation to the gland, but the optimal dose per gram of thyroid mass in calculated activity administration method is also under much debates. This prospective study has been designed in order to compare the effect of different calculated doses of radioiodine on Graves' disease treatment outcome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-65 hyperthyroid patients (Graves'disease)

排除标准

  • Pregnancy or lactation

研究组 & 干预措施

Low dose of I-131

Active Comparator

Patients with Graves' disease who will be treated with I-131, using 100 microcurie per gram (uCi/gr) of thyroid weight

干预措施: Low dose of I-131 (Drug)

Intermediate dose

Active Comparator

Patients with Graves' disease who will be treated with 150 microcurie (uCi) of I-131 per gram of thyroid weight.

干预措施: Intermediate dose (Drug)

High dose

Active Comparator

Patients with Graves' disease who will be treated with I-131 using 200 uCi/gr of thyroid weight.

干预措施: High dose (Drug)

结局指标

主要结局

change of thyroid related hormones blood level from baseline at 1,3,6 and 12 month

时间窗: 1,3,6,12 month

thyroid-stimulating hormone (TSH), T4, T3

次要结局

  • Rate of hypothyroidism status at 1, 3,6 and 12 month post RAI therapy(1,3,6,12 month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

S.R.ZAKAVI

Head of Nuclear Medicine Research Center

Mashhad University of Medical Sciences

研究点 (1)

Loading locations...

相似试验

Comparative Study of Different I-131 Doses in... | 临床试验